Q-omics provides the consensus-scored C5orf38 profile across patient tissues and cancer cell-line models. C5orf38 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, C5orf38 is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, C5orf38 RNA expression shows 11,073 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCEC, LUAD, and THYM as cancer lineages where C5orf38 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C5orf38 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C5orf38 survival associations across molecular data types. C5orf38 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C5orf38 RNA expression–survival associations across cancer types. High C5orf38 expression shows unfavorable associations in KIRP and HNSC, but favorable associations in UCEC, COAD, LUAD and LIHC. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for C5orf38 RNA expression.
This table summarizes C5orf38 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for C5orf38. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C5orf38 shows lower tumor expression in LUAD, KIRC, KICH, LUSC and KIRP and higher tumor expression in HNSC. The LUAD box plot shows higher C5orf38 RNA expression in normal versus tumor tissue (log2 FC = −3.581, t-test p < 0.001).
This table shows molecular features associated with C5orf38 in patient tissues and cancer cell lines. In patient samples, C5orf38 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, C5orf38 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
